Because pathology deserves more

Our mission is to transform pathology through AI-based tissue mining and standardization.

Because pathology deserves more

Visiopharm® is a world leader in AI-driven precision pathology software.

Visiopharm’s pioneering image analysis tools support thousands of scientists, pathologists, and image analysis experts in academic institutions, biopharmaceutical industry, and diagnostic centers. AI-based image analysis and tissue mining tools support research and drug development research worldwide, while CE-IVD APPs support primary diagnostics. With the most advanced and sophisticated artificial intelligence and deep learning, Visiopharm delivers tissue data mining tools, precision results, and workflows.

Visiopharm was founded in 2001 and is privately owned. The company operates internationally with over 750 licenses in more than 40 countries. The company headquarters are in Denmark’s Medicon Valley, with offices in Sweden, England, Germany, and the United States.

Privately-owned company

Visiopharm, a privately-owned company, was founded in 2001 by the Managing Director, and Chief Executive Officer, Michael Grunkin and the Chief Technical officer, Johan Doré Hansen, who both have a strong scientific and practical background in image analysis.

80+
employees

80+
employees

22
support experts

22
support experts

20
software engineers

20
software engineers

58%
Masters & PhDs

58%
Masters & PhDs

14
nationalities

14
nationalities

Leading scientific advancement

Our solutions are featured in over 2000 peer-reviewed scientific publications. Visiopharm is certified according to EN ISO 13485:2016, covering design, development, manufacture, installation, and service of in vitro diagnostics pathology software.

7
patents

7
patents

serving 90 % of the top big pharma companies

serving 90 % of the top big pharma companies

+2000
peer reviewed scientific publications

+2000
peer reviewed scientific publications

Technology & AI

Our company has grown into an international business with over 900 licenses in more than 38 countries. Our growing network of authorized distributors and partners support the growth of Visiopharm’s solutions on several continents including North America, Europe, and Asia.

120
ready-to-use APPS

120
ready-to-use APPS

8
CE-IVD APPs

8
CE-IVD APPs

100%
rooted in AI

100%
rooted in AI

Awards and Certificates

Frost & Sullivan – Global Digital Pathology Solutions 2019

Visiopharm Earns Acclaim from Frost & Sullivan for Transforming Anatomic Pathology. Frost & Sullivan recognizes Denmark-headquartered Visiopharm A/S with the 2019 Global Company of the Year Award. The award recognizes a high degree of innovation with products and technologies, and the resulting leadership in terms of customer value and market penetration.

Learn more

CIO Applications Top 25 Machine Learning Solution Providers 2019

Visiopharm was recognized by CIO Applications Magazine as CIO Applications Top 25 Machine Learning Solution Provider 2019. CIO Applications brings you the “Top 25 Machine Learning Solution Providers – 2019”. The CIO Application Magazine states: “The list features some of the most prominent machine solution providers in the industry that have excelled in their services and product portfolio in the ML space”.

Learn more

Børsen Gazelle Growth Accelerator Award

Visiopharm wins Denmark’s leading business newspaper “Dagblade Børsen” Gazelle Growth Accellerator, the prestigious award “Børsen Gazelle 2017” as an identification of Denmark’s absolute growth elite.

The award is given as a recognition to achieve a continuous growth in revenue or gross profit for the last four financial years, and which has, in total, more than doubled the revenue or the gross profit in the period.

Learn more

Danish EY Entrepreneur Of The Year™

Visiopharm was promoted two times for EY Entrepreneur of the Year in 2016 and 2017. We were placed among the top three nominees for the finalist in the Life Science category in 2017.

Ernst & Young, EY Entrepreneur Of The Year™ awards recognize and celebrate unstoppable entrepreneurs in their field. 

Learn more

We team up with

Visiopharm is an exclusive distributor of NanoZoomer whole slide scanners in the Netherlands and Denmark. Hamamatsu fuses cutting edge hardware technology with the philosophy of an intuitive interface design. As a result, the NanoZoomer series offer high productivity and user acceptance within multiple whole slide imaging application environments. Contact us to learn more.

CGI is a leading provider of end-to-end digital pathology solutions for a truly digital, highly efficient workflow that encompasses all processes from sample requisition to diagnosis. With more than 20 years of experience and profound domain expertise, CGI continues to improve and expand its pathology solutions, helping the public health sector in Denmark maintain its position as a world leader in pathology. CGI’s pathology solutions are used by all five regions in Denmark as well as in pathology labs in public and private hospitals in Denmark and abroad.

Corista delivers the industry’s most extensive array of workflow, analytical and collaborative tools for pathology. Medical centers can seamlessly integrate with LIS/EHRs in a unified digital environment of whole-slide, gross and static pathology images. Corista provides for a new level of interoperability for pathology, integrating WSI image scanning systems, image analytics and LIS/EHR platforms with a rich collaborative environment for physicians, patients, bio-tech and pharmaceutical scientists.

The aim of Nordic immunohistochemical Quality Control (NordiQC) is to promote the quality of immunohistochemistry and expand its clinical use by arranging schemes for immunohistochemical staining and providing examples of good protocols and other information including descriptions of epitopes and technical solutions. Visiopharm has a close collaboration with NordiQC on the development and validation of IHC APPs.

Visiopharm is a global distributor of ISENET’s Galileo CK family of TMA instruments provides an open architecture, and creates the perfect environment for client customizations including the use of different size blocks, and other unique features (i.e. use 96 well plates or Eppendorf vials for Tissue Core Nucleic Acid Extractions) including a record of core position and donor ID’s within an electronic report. Furthermore, this feature allows the possibility to export the xml file to any commercial digital scanner (Aperio, Hamamatsu, etc.) allowing the possibility to keep the digital scanner and visual imaging software in use in the lab.

Akoya Biosciences develops innovative solutions for life science research to enable spatially-resolved, quantitative tissue phenotyping at the cellular and sub-cellular level. The combined technologies of Phenoptics and CODEX are fueling advances in multiplex imaging by providing comprehensive solutions including instrumentation, reagents and tissue analysis software for biomarker discovery to translational research. Akoya Biosciences in headquartered in Menlo Park, CA.

Agilent Technologies Inc.  is a global leader in life sciences, diagnostics, and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions, and people provide trusted answers to customers’ most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide.

By seamlessly integrating Visiopharm’s image analysis (IA) suite into Proscia’s Concentriq® image management system (IMS), we’re creating a connected digital ecosystem that eliminates data silos and facilitates the introduction of analysis results into routine research. As a result, your users can make faster, more informed decisions in image-based research.

We aim to improve patient care through monitoring the quality of tests and their reporting, in an independent manner and on a not-for-profit basis. We are here to help ensure optimal quality in testing for the benefit of patients. We believe that the result of tests should be: Comparable, Safe, Clinically useful to the patient no matter where or when they are performed.

Success
Your message has been successfully sent!